Lupin Gets US FDA Nod for Prucalopride Tablets, Expands GI Portfolio in the U.S.

Unknown Apr 02, 2026 800 Views

Lupin Ltd. (NSE: LUPN) informed that it has obtained final US FDA approval on its Abbreviated New Drug Application (ANDA) of Prucalopride Tablets, which is a generic version of Takeda Pharmaceuticals' Motegrity® (Prucalopride Succinate). The development is a significant addition to Lupin&...